US20090318704A1 - Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide - Google Patents

Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide Download PDF

Info

Publication number
US20090318704A1
US20090318704A1 US12/376,083 US37608307A US2009318704A1 US 20090318704 A1 US20090318704 A1 US 20090318704A1 US 37608307 A US37608307 A US 37608307A US 2009318704 A1 US2009318704 A1 US 2009318704A1
Authority
US
United States
Prior art keywords
compound
formula
combination
hours
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/376,083
Other languages
English (en)
Inventor
John F. Reichwein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/376,083 priority Critical patent/US20090318704A1/en
Publication of US20090318704A1 publication Critical patent/US20090318704A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • N-(2-acetyl-4,6-dimethylphenyl)-3- ⁇ [(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl ⁇ -2-thiophenecarboxamide is an endothelin antagonist (U.S. Pat. No. 6,686,382).
  • Endothelin antagonists are useful for the treatment of hypertension such as peripheral circulatory failure, heart disease such as angina pectoris, cardiomyopathy, arteriosclerosis, myocardial infarction, pulmonary hypertension, vasospasm, vascular restenosis, Raynaud's disease, cerebral stroke such as cerebral arterial spasm, cerebral ischemia, late phase cerebral spasm after subarachnoid hemorrhage, asthma, bronchoconstriction, renal failure, particularly post-ischemic renal failure, cyclosporine nephrotoxicity such as acute renal failure, colitis, as well as other inflammatory diseases, endotoxic shock caused by or associated with endothelin, and other diseases in which endothelin has been implicated.
  • hypertension such as peripheral circulatory failure, heart disease such as angina pectoris, cardiomyopathy, arteriosclerosis, myocardial infarction, pulmonary hypertension, vasospasm, vascular restenosis, Raynaud's disease, cerebral stroke such as cerebral
  • a process for preparing the compound of Formula (I), or a pharmaceutically acceptable derivative thereof wherein the process involves a step of reacting a compound of Formula (II):
  • pharmaceutically acceptable derivatives of a compound include salts, esters, enol ethers, enol esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, solvates, hydrates or prodrugs thereof.
  • Such derivatives may be readily prepared by those of skill in this art using known methods for such derivatization.
  • the compounds produced may be administered to animals or humans without substantial toxic effects and either are pharmaceutically active or are prodrugs.
  • salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1′-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and other metal salts, such as but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides, such
  • esters include, but are not limited to, alkyl, alkenyl, alkynyl, alk(en)(yn)yl, aryl, aralkyl, and cycloalkyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfonic acids, sulfinic acids and boronic acids.
  • Pharmaceutically acceptable enol ethers include, but are not limited to, derivatives of formula C ⁇ C(OR) where R is hydrogen, alkyl, alkenyl, alkynyl, alk(en)(yn)yl, aryl, aralkyl, or cycloalkyl.
  • enol esters include, but are not limited to, derivatives of formula C ⁇ C(OC(O)R) where R is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, or cycloalkyl.
  • Pharmaceutically acceptable solvates and hydrates are complexes of a compound with one or more solvent or water molecules, or 1 to about 100, or 1 to about 10, or one to about 2, 3 or 4, solvent or water molecules.
  • the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures. It is to be understood that the chiral centers of the compounds provided herein may undergo epirnerization in vivo. As such, one of skill in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.
  • alkyl refers to an unbranched or branched hydrocarbon chain.
  • An alkyl group may be unsubstituted or substituted with one or more heteroatoms.
  • alkenyl refers to an unbranched or branched hydrocarbon chain comprising one or more double bonds.
  • the double bond of an alkenyl group may be unconjugated or conjugated to another unsaturated group.
  • An alkenyl group may be unsubstituted or substituted with one or more heteroatoms.
  • alkynyl refers to an unbranched or branched hydrocarbon chain comprising one of more triple bonds therein.
  • the triple bond of an alkynyl group may be unconjugated or conjugated to another unsaturated group.
  • An alkynyl group may be unsubstituted or substituted with one or more heteroatoms.
  • alk(en)(yn)yl refers to an unbranched or branched hydrocarbon group comprising at least one double bond and at least one triple bond.
  • the double bond or triple bond of an alk(en)(yn)yl group may be unconjugated or conjugated to another unsaturated group.
  • An alk(en)(yn)yl group may be unsubstituted or substituted with one or more heteroatoms.
  • Exemplary alkyl, alkenyl, alkynyl, and alk(en)(yn)yl groups herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl, isohexyl, allyl (propenyl) and propargyl (propynyl).
  • aryl refers to aromatic monocyclic or multicyclic groups containing from 6 to 19 carbon atoms.
  • Aryl groups include, but are not limited to groups such as unsubstituted or substituted fluorenyl, unsubstituted or substituted phenyl, and unsubstituted or substituted naphthyl.
  • heteroaryl refers to a monocyclic or multicyclic aromatic ring system, in certain embodiments, of about 5 to about 15 members where one or more, in one embodiment 1 to 3, of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen or sulfur.
  • the heteroaryl group may be optionally fused to a benzene ring.
  • Heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolinyl or isoquinolinyl.
  • halo refers to F, Cl, Br or I.
  • base refers to any compound that accepts protons in water or solvent.
  • exemplary bases include, but are not limited to, alkali metal hydroxides and alkali metal alkoxides (i.e., MOR, wherein M is an alkali metal such as but not limited to potassium, lithium, or sodium and R is hydrogen, alkyl, alkenyl, alkynyl, or alk(en)(yn)yl) such as but not limited to potassium hydroxide, potassium tert-butoxide, potassium tert-pentoxide, sodium hydroxide, sodium tert-butoxide, lithium hydroxide, etc.); other hydroxides such as but not limited to magnesium hydroxide (Mg(OH) 2 ), calcium hydroxide (Ca(OH) 2 ), or barium hydroxide (Ba(OH) 2 ); alkali metal hydrides (i.e., MH, wherein M is as defined above) such as but not limited to sodium hydride, potassium hydr
  • solvent refers to any liquid that completely or partially dissolves a solid, liquid, or gaseous solute, resulting in a solution such as but not limited to hexane, benzene, toluene, diethyl ether, chloroform, ethyl acetate, dichloromethane, carbon tetrachloride, 1,4-dioxane, tetrahydrofuran, glyme, diglyme, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, or N-methyl-2-pyrrolidone.
  • dehydrating agent refers to any compound that promotes the formation of carboxamides from carboxylic acids, such as but not limited to thionyl chloride, sulfuryl chloride, a carbodiimide, an anhydride or a mixed anhydride, a phenol (such as but not limited to nitrophenol, pentafluorophenol, or phenol), or a compound of Formula (A):
  • each of X and Y is independently an unsubstituted or substituted heteroaryl group (such as but not limited to imidazolyl, benzimidazolyl, or benzotriazolyl).
  • dehydrating agents further include, but are not limited to, benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), N,N′-carbonyldiimidazole (CDI), 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide (EDC), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra
  • acid refers to any compound that contains hydrogen and dissociates in water or solvent to produce positive hydrogen ions, as well as Lewis acids, including but not limited to hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trihaloacetic acids (such as but not limited to trifluoroacetic acid or trichloroacetic acid), hydrogen bromide, maleic acid, sulfonic acids (such as but not limited to toluenesulfonic acids or camphorsulfonic acids), propionic acids (such as but not limited to (R)-chloropropionic acid), phthalamic acids (such as but not limited to N-[(R)-1-(1-naphthyl)ethyl]phthalamic acid), tartaric acids (such as but not limited to L-tartaric acid or dibenzyl-L-tartaric acid), lactic acids, camphoric acids, aspartic acids, or citronellic acids.
  • Lewis acids including but not limited to hydrochlor
  • reactants, compounds, solvents, acids, bases, catalysts, agents, reactive groups, or the like may be added individually, simultaneously, separately, and in any order. Furthermore, it is to be understood that reactants, compounds, acids, bases, catalysts, agents, reactive groups, or the like may be pre-dissolved in solution and added as a solution (including, but not limited to, aqueous solutions). In addition, it is to be understood that reactants, compounds, solvents, acids, bases, catalysts, agents, reactive groups, or the like may be in any molar ratio.
  • reactants, compounds, solvents, acids, bases, catalysts, agents, reactive groups, or the like may be formed in situ.
  • the preparation of the compound of Formula (I) or a pharmaceutically acceptable derivative thereof as depicted in Scheme A may occur in the presence of any base or any combination of bases.
  • the base is (or combination of bases are) generated in situ.
  • the base is (or the combination of bases includes) an alkali metal hydride.
  • the base is sodium hydride.
  • the preparation of the compound of Formula (I) or a pharmaceutically acceptable derivative thereof as depicted in Scheme A may occur in any solvent or any combination of solvents.
  • the solvent is (or the combination of solvents contains) 1,4-dioxane, tetrahydrofuran, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, glyme, diglyme, dimethylacetamide, or N-methyl-2-pyrrolidone.
  • the solvent is dimethylformamide.
  • the base is sodium hydride and the solvent is dimethylformamide.
  • the preparation of the compound of Formula (I) or a pharmaceutically acceptable derivative thereof as depicted in Scheme A may occur at any reaction temperature.
  • the reaction temperature may vary from about ⁇ 78° C. to about 100° C.
  • the reaction temperature may vary from about ⁇ 50° C. to about 80° C.
  • the reaction temperature may vary from about ⁇ 40° C. to about 60° C.
  • the reaction temperature may vary from about ⁇ 25° C. to about 30° C.
  • the reaction temperature may vary from about ⁇ 10° C. to about 10° C.
  • the reaction temperature is about 0° C.
  • the base is sodium hydride
  • the solvent is dimethylformamide
  • the reaction temperature is about 0° C.
  • reaction time is from about 30 minutes to about 24 hours. In some embodiments, the reaction time is from about 2 hours to about 3 hours.
  • the base is sodium hydride
  • the solvent is dimethylformamide
  • the reaction temperature is about 0° C.
  • the reaction time is from about 2 hours to about 3 hours.
  • the preparation of the compound of Formula (I) or a pharmaceutically acceptable derivative thereof as depicted in Scheme A may occur at any molar ratio according to a person of ordinary skill in the art.
  • the molar ratio of the compound of Formula (III) to the compound of Formula (II) is from about 3:1 to about 1:1.
  • the molar ratio of the compound of Formula (II) to the compound of Formula (III) is from about 3:1 to about 1:1.
  • the molar ratio of the compound of Formula (III) to the compound of Formula (II) is about 1:1.
  • the base is sodium hydride
  • the solvent is dimethylformamide
  • the reaction temperature is about 0° C.
  • the reaction time is from about 2 hours to about 3 hours
  • the molar ratio is about 1:1.
  • a process for preparing a compound of Formula (II) or a pharmaceutically acceptable derivative thereof by reacting a compound of Formula (IV) with a dehydrating agent or a combination of dehydrating agents as depicted in Scheme B.
  • a process for preparing a compound of Formula (II) or a pharmaceutically acceptable derivative thereof by reacting a compound of Formula (IVa) with a dehydrating agent of a combination of dehydrating agents as depicted in Scheme B1.
  • the preparation of the compound of Formula (IVa) may be prepared using methods known to those of ordinary skill in the art.
  • the compound of Formula (IVa) may be prepared using methods similar to those used in the preparation of the compound of Formula (IV).
  • the preparation of the compound of Formula (II) or a pharmaceutically acceptable derivative thereof as depicted in Scheme B or Scheme B1 may occur with any dehydrating agent or any combination of dehydrating agents according to a person of ordinary skill in the art.
  • the dehydrating agent is, or the combination of dehydrating agents are, generated in situ.
  • the dehydrating agent is (or the combination of dehydrating agents contains) thionyl chloride, sulfuryl chloride, 4-dimethylaminopyridine, a carbodiimide, an anhydride or a mixed anhydride, a phenol, or a compound of Formula (A):
  • the dehydrating agent is (or combination of dehydrating agents contains) benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), N,N′-carbonyldiimidazole (CDI), 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), 1-ethyl-3-(3-dimethyllaminopropyl)carbodiimide (EDC), 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxybenzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluor
  • the preparation of the compound of Formula (II) or a pharmaceutically acceptable derivative thereof as depicted in Scheme B or Scheme B1 may occur in any solvent or any combination of solvents.
  • the solvent is, or the combination of solvents contains, hexane, benzene, toluene, diethyl ether, chloroform, ethyl acetate, dichloromethane, carbon tetrachloride, 1,4-dioxane, tetrahydrofuran, glyme, diglyme, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, or N-methyl-2-pyrrolidone.
  • the solvent is ethyl acetate.
  • the dehydrating agent is N,N′-carbonyldiimidazole and the solvent is ethyl acetate.
  • reaction temperature is from about 0° C. to about 100° C. In some embodiments, the reaction temperature is from about 20° C. to about 80° C. In some embodiments, the reaction temperature is from about 40° to about 60° C. In some embodiments, the reaction temperature is from about 20° C. to about 30° C.
  • the dehydrating agent is N,N′-carbonyldiimidazole
  • the solvent is ethyl acetate
  • the reaction temperature is from about 20° C. to about 30° C.
  • reaction time is from about 30 minutes to about 5 hours. In some embodiments, the reaction time is from about 3 hours to about 5 hours. In some embodiments, the reaction time is about 4 hours.
  • the dehydrating agent is N,N′-carbonyldiimidazole
  • the solvent is ethyl acetate
  • the reaction temperature is from about 20° C. to about 30° C.
  • the reaction time is about 4 hours.
  • the preparation of the compound of Formula (II) or a pharmaceutically acceptable derivative thereof as depicted in Scheme B or Scheme B1 may occur at any molar ratio according to a person of ordinary skill in the art.
  • the molar ratio of N,N′-carbonyldiimidazole to the compound of Formula (IV) is from about 5:1 to about 1:1.
  • the molar ratio of N,N′-carbonyldiimidazole to the compound of Formula (IV) is about 1.2:1.
  • the dehydrating agent is N,N′-carbonyldiimidazole
  • the solvent is ethyl acetate
  • the reaction temperature is from about 20° C. to about 30° C.
  • the reaction time is about 4 hours
  • the molar ratio of N,N′-carbonyldiimidazole to the compound of Formula (IV) is about 1.2:1.
  • the preparation of the compound of Formula (IV) or a pharmaceutically acceptable derivative thereof as depicted in Scheme C may occur in the presence of any base or any combination of bases.
  • the base is (or the combination of bases are) generated in situ.
  • the base is (or the combination of bases contains) a hydroxide.
  • the base is (or the combination of bases contains) potassium hydroxide, sodium hydroxide, lithium hydroxide, magnesium hydroxide, calcium hydroxide, or barium hydroxide.
  • the base is sodium hydroxide.
  • the preparation of the compound of Formula (IV) or a pharmaceutically acceptable derivative thereof as depicted in Scheme C may occur in any solvent or any combination of solvents according to a person of ordinary skill in the art.
  • the solvent is (or the combination of solvents contains) hexane, benzene, toluene, diethyl ether, chloroform, ethyl acetate, dichloromethane, carbon tetrachloride, 1,4-dioxane, tetrahydrofuran, glyme, diglyme, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, or N-methyl-2-pyrrolidone.
  • the solvent is tetrahydrofuran.
  • the base is sodium hydroxide and the solvent is tetrahydrofuran.
  • reaction temperature is from about 0° C. to about 100° C. In some embodiments, the reaction temperature is from about 20° C. to about 80° C. In some embodiments, the reaction temperature is from about 40° to about 60° C. In some embodiments, the reaction temperature is from about 20° C. to about 30° C.
  • the base is sodium hydroxide
  • the solvent is tetrahydrofuran
  • the reaction temperature is from about 20° C. to about 30° C.
  • the preparation of the compound of Formula (IV) or a pharmaceutically acceptable derivative thereof as depicted in Scheme C may occur at any reaction time according to a person of ordinary skill in the art. In some embodiments, the reaction time is from about 2 hours to about 36 hours.
  • the base is sodium hydroxide
  • the solvent is tetrahydrofuran
  • the reaction temperature is from about 20° C. to about 30° C.
  • the reaction time is from about 2 hours to about 36 hours.
  • the preparation of the compound of Formula (IV) or a pharmaceutically acceptable derivative thereof as depicted in Scheme C may occur in the presence of any acid or any combination of acids according to a person of ordinary skill in the art.
  • the acid is (or combination of acids are) generated in situ.
  • a process for preparing a compound of Formula (VI) or a pharmaceutically acceptable derivative by reacting a compound of Formula (VII) with a compound of Formula (VIII) or a salt thereof as depicted in Scheme D.
  • the base is (or combination of bases are) generated in situ.
  • the base is (or combination of bases contains) a tertiary amine, aromatic amine, non-nucleophilic alkali metal amide, alkyl lithium, alkenyl lithium, alkynyl lithium, alk(en)(yn)yl lithium, alkyl magnesium halide, alkenyl magnesium halide, alkynyl magnesium halide, or alk(en)(yn)yl magnesium halide.
  • the base is (or combination of bases contains) dimethylethyl amine, trimethylamine, triethylamine, tributylamine, N-ethyldiisopropylamine, N-methylmorpholine, 1,8-diazabicyclo[5.4.0]-7-undecene, 1,5-diazabicyclo[4.3.0]-5-nonene, tetramethylenediamine, pyridine, collidine, lutidine, picoline, quinoline, or N,N-dimethylaniline.
  • the base is pyridine.
  • reaction temperature is from about 0° C. to about 100° C. In some embodiments, the reaction temperature is from about 20° C. to about 80° C. In some embodiments, the reaction temperature is from about 40° to about 60° C. In some embodiments, the reaction temperature is from about 20° C. to about 30° C.
  • the base is pyridine and the reaction temperature is from about 20° C. to about 30° C.
  • reaction time is from about 2 hours to about 36 hours.
  • the base is pyridine
  • the reaction temperature is from about 20° C. to about 30° C.
  • the reaction time if from about 2 hours to about 36 hours.
  • the preparation of the compound of Formula (VI) or a pharmaceutically acceptable derivative thereof as depicted in Scheme D may occur in any solvent or any combination of solvents according to a person of ordinary skill in the art. Further, the preparation of the compound of Formula (VI) or a pharmaceutically acceptable derivative as depicted in Scheme D in the presence of a base or a combination of bases may occur in any solvent or combination of solvents according to a person of ordinary skill in the art.
  • the solvent is (or combination of solvents contains) hexane, benzene, toluene, diethyl ether, chloroform, ethyl acetate, dichloromethane, carbon tetrachloride, 1,4-dioxane, tetrahydrofuran, glyme, diglyme, acetone, acetonitrile, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, and N-methyl-2-pyrrolidone.
  • the preparation of the compound of Formula (VI) or a pharmaceutically acceptable derivative thereof as depicted in Scheme D may occur at any molar ratio according to a person of ordinary skill in the art.
  • the molar ratio of the compound of Formula (VIII) to the compound of Formula (VII) is from about 3:1 to about 1:1.
  • the molar ratio of the compound of Formula (VII) to the compound of Formula (VIII) is from about 3:1 to about 1:1.
  • the molar ratio of the compound of Formula (VIII) to the compound of Formula (VII) is about 1.1:1.
  • the base is pyridine
  • the reaction temperature is from about 20° C. to about 30° C.
  • the reaction time if from about 2 hours to about 36 hours
  • the molar ratio of the compound of Formula (VIII) to the compound of Formula (VII) is about 1.1:1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
US12/376,083 2006-08-04 2007-08-03 Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide Abandoned US20090318704A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/376,083 US20090318704A1 (en) 2006-08-04 2007-08-03 Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83563606P 2006-08-04 2006-08-04
US12/376,083 US20090318704A1 (en) 2006-08-04 2007-08-03 Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide
PCT/US2007/017391 WO2008019096A1 (en) 2006-08-04 2007-08-03 Processes for the preparation of n-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino}sulfonyl}-2-thiophenecarboxamide

Publications (1)

Publication Number Publication Date
US20090318704A1 true US20090318704A1 (en) 2009-12-24

Family

ID=38819265

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/376,083 Abandoned US20090318704A1 (en) 2006-08-04 2007-08-03 Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide
US11/890,201 Expired - Fee Related US7754892B2 (en) 2006-08-04 2007-08-03 Processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
US12/793,098 Abandoned US20100240904A1 (en) 2006-08-04 2010-06-03 Processes for the preparation of n-(2-acetyl-4,6-dimethylphenyl)-3--2-thiophenecarboxamide

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/890,201 Expired - Fee Related US7754892B2 (en) 2006-08-04 2007-08-03 Processes for the preparation of N-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
US12/793,098 Abandoned US20100240904A1 (en) 2006-08-04 2010-06-03 Processes for the preparation of n-(2-acetyl-4,6-dimethylphenyl)-3--2-thiophenecarboxamide

Country Status (16)

Country Link
US (3) US20090318704A1 (es)
JP (1) JP2009545631A (es)
KR (1) KR20090036126A (es)
CN (1) CN101501017A (es)
AT (1) ATE466852T1 (es)
AU (1) AU2007281965B8 (es)
CA (1) CA2659884A1 (es)
DE (1) DE602007006327D1 (es)
DK (1) DK2069323T3 (es)
ES (1) ES2344438T3 (es)
IL (1) IL196605A0 (es)
MX (1) MX2009001046A (es)
NO (1) NO20090347L (es)
PT (1) PT2069323E (es)
WO (1) WO2008019096A1 (es)
ZA (1) ZA200900369B (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006461A (es) 1999-12-31 2003-09-05 Texas Biotechnology Corp Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.

Also Published As

Publication number Publication date
AU2007281965A1 (en) 2008-02-14
JP2009545631A (ja) 2009-12-24
AU2007281965B8 (en) 2010-09-02
KR20090036126A (ko) 2009-04-13
WO2008019096A1 (en) 2008-02-14
CA2659884A1 (en) 2008-02-14
CN101501017A (zh) 2009-08-05
AU2007281965B2 (en) 2010-08-12
US20080086011A1 (en) 2008-04-10
ATE466852T1 (de) 2010-05-15
PT2069323E (pt) 2010-07-05
ES2344438T3 (es) 2010-08-26
US7754892B2 (en) 2010-07-13
IL196605A0 (en) 2009-11-18
DE602007006327D1 (de) 2010-06-17
US20100240904A1 (en) 2010-09-23
NO20090347L (no) 2009-02-19
DK2069323T3 (da) 2010-08-02
ZA200900369B (en) 2010-04-28
MX2009001046A (es) 2009-03-10

Similar Documents

Publication Publication Date Title
KR102384529B1 (ko) 4-알콕시-3-(아실 또는 알킬)옥시피콜린아미드의 제조 방법
WO2016181414A1 (en) Process for the synthesis of ivacaftor and related compounds
WO2010121382A1 (en) Process for making indole cyclopropyl amide derivatives
US20090318704A1 (en) Processes for the Preparation of N-(2-Acetyl-4,6-Dimethylphenyl)-3--2-Thiophenecarboxamide
EP2069323B1 (en) Processes for the preparation of n-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
CN103917531B (zh) 米卡芬净中间体的制备
US20080086010A1 (en) Processes for the preparation of 4-chloro-3-methyl-5-(2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)-3-thienylsulfonamido)isoxazole
KR100687001B1 (ko) 아즈트레오남의 제법
CN104610280A (zh) 一种头孢噻吩酸的制备方法
MXPA04005863A (es) Compuestos inhibidores de lipasa pancreatica, su sintesis y uso.
CN104230956A (zh) 一种头孢西丁的制备方法
CN103626845B (zh) 作为糖原磷酸化酶抑制剂的芳基并吡咯-2-甲酰胺二肽衍生物、其制备方法及医药用途
RU2136686C1 (ru) Производные глутаминовой кислоты (варианты), фармацевтическая композиция, способ ингибирования роста и пролиферации клеток, производные тиофенкарбоновой кислоты (варианты)
PT92890A (pt) Processo para a preparacao de derivados de cefalosporina e de composicoes farmaceuticas que os contem
WO2009048274A2 (en) Benzofuran and benzothiophene derivatives substituted with amide, process for the preparation thereof, and pharmaceutical compositions containing the same
AU2006292603A1 (en) Process for the preparation of benzo (e) (1,2,4) triazepin-2-one derivatives
CN100378085C (zh) 一种5-烷基-1、3、4-噁二唑酮的制备方法
CN104744292A (zh) (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
HK1130777A (en) Processes for the preparation of n-(2-acetyl-4,6-dimethylphenyl)-3-{[(3,4 dimethyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxamide
NO752901L (es)
JP2000309591A (ja) ジヒドロベンズ［ｃ］チオフェン化合物
JPS58116418A (ja) 抗菌性医薬組成物
CN104163803B (zh) 一种头孢洛林酯的合成方法
KR930005174B1 (ko) 항생물질 유도체의 제조방법
KR20120140230A (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION